The use of real-world data to address questions of patient safety
Authors:
- 13 December 2019
- journal article
- research article
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 59 (1) , 26-30
Abstract
Pharmacovigilance registries of biologics were established to evaluate the risk of adverse events that may be missed in trials due to shorter durations and homogeneous samples. This review will present the strengths and weaknesses of registry data in addressing patient safety issues. Since their inception, scope has broadened because registries represent a relatively inexpensive approach to answering many clinical questions, both research and non-research focused. They achieve high statistical power, allow direct comparability, and offer a level of detail about adverse events not possible with trial data. Registries have been central in clarifying the risk of infection and malignancy with anti-TNF therapy, despite the limitations of selection and channelling bias, incomplete case capture, unmeasured confounding, and the inability to infer causality. Routinely collected data from electronic health records and national audits offer alternative real-world resources, further assisting patients and clinicians in understanding the risks of biologic therapy choices.Keywords
Funding Information
- AbbVie
This publication has 20 references indexed in Scilit:
- Thiazolidinedione safetyExpert Opinion on Drug Safety, 2012
- Treatment benefit or survival of the fittest: what drives the time-dependent decrease in serious infection rates under TNF inhibition and what does this imply for the individual patient?Annals of the Rheumatic Diseases, 2011
- Integrated safety in tocilizumab clinical trialsArthritis Research & Therapy, 2011
- Anti-TNF therapy is associated with an increased risk of serious infections in patients with rheumatoid arthritis especially in the first 6 months of treatment: updated results from the British Society for Rheumatology Biologics Register with special emphasis on risks in the elderlyRheumatology, 2010
- The safety of anti-tumour necrosis factor treatments in rheumatoid arthritis: meta and exposure-adjusted pooled analyses of serious adverse eventsAnnals of the Rheumatic Diseases, 2009
- Time-dependent increase in risk of hospitalisation with infection among Swedish RA patients treated with TNF antagonistsAnnals of the Rheumatic Diseases, 2007
- The Risk of Lymphoma Development in Autoimmune DiseasesArchives of internal medicine (1960), 2005
- Haematopoietic malignancies in rheumatoid arthritis: lymphoma risk and characteristics after exposure to tumour necrosis factor antagonistsAnnals of the Rheumatic Diseases, 2005
- Tumour necrosis factor blockers do not increase overall tumour risk in patients with rheumatoid arthritis, but may be associated with an increased risk of lymphomasAnnals of the Rheumatic Diseases, 2005
- COX-2 selective non-steroidal anti-inflammatory drugs and risk of serious coronary heart diseaseThe Lancet, 2002